Tardive dyskinesia pipeline review, q3 2011


Published on

Published in: Business, Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Tardive dyskinesia pipeline review, q3 2011

  1. 1. Tardive Dyskinesia - Pipeline Review, Q3 2011Tardive Dyskinesia - Pipeline Review, Q3 2011SummaryGlobal Markets Direct’s, Tardive Dyskinesia - Pipeline Review, Q3 2011, providesan overview of the Tardive Dyskinesia therapeutic pipeline. This report providesinformation on the therapeutic development for Tardive Dyskinesia, complete withlatest updates, and special features on late-stage and discontinued projects. It alsoreviews key players involved in the therapeutic development for Tardive Dyskinesia.Tardive Dyskinesia - Pipeline Review, Q3 2011 is built using data and informationsourced from Global Markets Direct’s proprietary databases, Company/Universitywebsites, SEC filings, investor presentations and featured press releases fromcompany/university sites and industry-specific third party sources, put together byGlobal Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Tardive Dyskinesia.- A review of the Tardive Dyskinesia products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.- Coverage of the Tardive Dyskinesia pipeline on the basis of therapeutic class,route of administration and molecule type.- Profiles of late-stage pipeline products featuring sections on product description,mechanism of action and research & development progress.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Browse All Pharmaceuticals Market Research ReportsReasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Tardive Dyskinesia.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players with the mostpromising pipeline.- Devise corrective measures for pipeline projects by understanding TardiveDyskinesia pipeline depth and focus of Tardive Dyskinesia therapeutics.- Develop and design in-licensing and out-licensing strategies by identifyingprospective partners with the most attractive projects to enhance and expand
  2. 2. business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects andunderstanding the factors that drove them from pipeline.Table of ContentsTable of Contents 2List of Tables 3List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Tardive Dyskinesia Overview 6Therapeutics Development 7An Overview of Pipeline Products for Tardive Dyskinesia 7Tardive Dyskinesia Therapeutics under Development by Companies 9Tardive Dyskinesia Therapeutics under Investigation by Universities/Institutes 10Late Stage Products 11Comparative Analysis 11Mid Clinical Stage Products 12Comparative Analysis 12Tardive Dyskinesia Therapeutics - Products under Development by Companies 13Tardive Dyskinesia Therapeutics - Products under Investigation byUniversities/Institutes 14Companies Involved in Tardive Dyskinesia Therapeutics Development 15Neurocrine Biosciences, Inc. 15Medicure Inc. 15Tardive Dyskinesia - Therapeutics Assessment 16Assessment by Monotherapy Products 16Assessment by Route of Administration 17Assessment by Molecule Type 19Drug Profiles 21NBI-98854 - Drug Profile 21Product Description 21Mechanism of Action 21R&D Progress 21TARDOXAL - Drug Profile 22Product Description 22Mechanism of Action 22R&D Progress 22Piracetam - Drug Profile 23Product Description 23Mechanism of Action 23R&D Progress 23Tardive Dyskinesia Therapeutics – Drug Profile Updates 24Tardive Dyskinesia Therapeutics - Discontinued Products 25Tardive Dyskinesia - Featured News 26Jun 23, 2011: Neurocrine Biosciences Announces Notice Of Allowance For
  3. 3. Composition Of Matter Patent On VMAT2 Inhibitor 26Apr 05, 2011: Neurocrine Biosciences Announces Successful Phase IIa Clinical TrialFor VMAT2 Inhibitor 26Oct 18, 2010: Neurocrine Completes Reports Second Phase I Clinical Trial Of NBI-98854 27Apr 13, 2010: Neurocrine Biosciences Announces The Initiation Of Second VMAT2Phase I Clinical Trial 28Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial28Dec 21, 2009: Neurocrine Announces VMAT2 Inhibitor 29Mar 11, 2009: Medicure Inc Announces Regulatory Approval Of A Phase II ClinicalTrial Of Avastrem For The Treatment Of Tardive Dyskinesia Medicure Inc.Announces Regulatory Approval of a Phase II Clinical Trial of Avastrem for theTreatment o 29Jan 12, 2009: Medicure Announces Regulatory Approval Of A Phase II Clinical TriaLOf Avastrem For The Treatment Of Tardive Dyskinesia 30Apr 03, 2008: Proximagen Neuroscience Plc - Interim results for the six monthsended 31 May 2008 30Appendix 31Methodology 31Coverage 31Secondary Research 31Primary Research 31Expert Panel Validation 32Contact Us 32Disclaimer 32About Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Pagehttp://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: +1-888-989-8004E-mail: sales@reportsandreports.comhttp://www.reportsandreports.comVisit our Market Research Blog